The DOI matches its Crossref record; 241 of the 241 references it cites were found in a registry or an index.
“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Genomic signatures to guide the use of chemotherapeutics
Potti, A., Dressman, H. K., Bild, A., Riedel, R. F., Chan, G., Sayer, R., Cragun, J., Cottrill, H., Kelley, M. J., Petersen, R., et al. (2006) · Nature Medicine · doi:10.1038/nm1491 · Cited by 593
RetractedEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Photodynamic therapy for cancer
Dolmans, D. E. J. G. J., Fukumura, D., & Jain, R. K. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1071 · Cited by 6,758
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
A clearer vision for in vivo imaging
Weissleder, R. (2001) · Nature Biotechnology · doi:10.1038/86684 · Cited by 3,839
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Biodegradable polymeric nanoparticles as drug delivery devices
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00339-4 · Cited by 3,549
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
Thermo- and pH-responsive polymers in drug delivery☆
SCHMALJOHANN, D. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.020 · Cited by 3,023
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
PI3K/Akt signalling pathway and cancer
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.007 · Cited by 2,443
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
Intra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,899
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Gold nanorods and their plasmonic properties
Chen, H., Shao, L., Li, Q., & Wang, J. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35367a · Cited by 1,838
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Nano-graphene in biomedicine: theranostic applications
Yang, K., Feng, L., Shi, X., & Liu, Z. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35342c · Cited by 1,634
Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Khlebtsov, N., & Dykman, L. (2011) · Chem. Soc. Rev. · doi:10.1039/c0cs00018c · Cited by 1,584
VEGF and the quest for tumour angiogenesis factors
Ferrara, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc909 · Cited by 1,536
Erez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
Gold Nanocages: Synthesis, Properties, and Applications
Skrabalak, S. E., Chen, J., Sun, Y., Lu, X., Au, L., Cobley, C. M., & Xia, Y. (2008) · Accounts of Chemical Research · doi:10.1021/ar800018v · Cited by 1,447
Inflammation meets cancer, with NF-κB as the matchmaker
Ben-Neriah, Y., & Karin, M. (2011) · Nature Immunology · doi:10.1038/ni.2060 · Cited by 1,373
Cheng, R., Feng, F., Meng, F., Deng, C., Feijen, J., & Zhong, Z. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.01.030 · Cited by 1,360
Targeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290
Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,259
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
Treating metastatic cancer with nanotechnology
Schroeder, A., Heller, D. A., Winslow, M. M., Dahlman, J. E., Pratt, G. W., Langer, R., Jacks, T., & Anderson, D. G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3180 · Cited by 1,159
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
Is NF-κB a good target for cancer therapy? Hopes and pitfalls
Baud, V., & Karin, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2781 · Cited by 1,061
Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052
Computationally Guided Photothermal Tumor Therapy Using Long-Circulating Gold Nanorod Antennas
von Maltzahn, G., Park, J.-H., Agrawal, A., Bandaru, N. K., Das, S. K., Sailor, M. J., & Bhatia, S. N. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4242 · Cited by 1,051
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.015 · Cited by 988
Zhang, Z., Wang, L., Wang, J., Jiang, X., Li, X., Hu, Z., Ji, Y., Wu, X., & Chen, C. (2012) · Advanced Materials · doi:10.1002/adma.201104714 · Cited by 974
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
Gene Therapy Progress and Prospects: Nonviral vectors
Niidome, T., & Huang, L. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301923 · Cited by 963
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 938
Synergistic effect of chemo-photothermal therapy using PEGylated graphene oxide
Zhang, W., Guo, Z., Huang, D., Liu, Z., Guo, X., & Zhong, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.071 · Cited by 891
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
Zhao, C., Chen, A., Jamieson, C. H., Fereshteh, M., Abrahamsson, A., Blum, J., Kwon, H. Y., Kim, J., Chute, J. P., Rizzieri, D., et al. (2009) · Nature · doi:10.1038/nature07737 · Cited by 869
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
Sinha, R., Kim, G. J., Nie, S., & Shin, D. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0141 · Cited by 801
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 801
Gold nanostructures: a class of multifunctional materials for biomedical applications
Cobley, C. M., Chen, J., Cho, E. C., Wang, L. V., & Xia, Y. (2011) · Chem. Soc. Rev. · doi:10.1039/b821763g · Cited by 792
Understanding the Toxicity of Carbon Nanotubes
Liu, Y., Zhao, Y., Sun, B., & Chen, C. (2013) · Accounts of Chemical Research · doi:10.1021/ar300028m · Cited by 760
Gold Nanocages as Photothermal Transducers for Cancer Treatment
Chen, J., Glaus, C., Laforest, R., Zhang, Q., Yang, M., Gidding, M., Welch, M. J., & Xia, Y. (2010) · Small · doi:10.1002/smll.200902216 · Cited by 691
Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization
Fukumura, D., & Jain, R. K. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.05.003 · Cited by 691
Nanoparticle-based combination therapy toward overcoming drug resistance in cancer
Hu, C.-M. J., & Zhang, L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.008 · Cited by 686
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
ATP-triggered anticancer drug delivery
Mo, R., Jiang, T., DiSanto, R., Tai, W., & Gu, Z. (2014) · Nature Communications · doi:10.1038/ncomms4364 · Cited by 682
The History of Photodetection and Photodynamic Therapy¶
Ackroyd, R., Kelty, C., Brown, N., & Reed, M. (2007) · Photochemistry and Photobiology · doi:10.1562/0031-8655(2001)0740656thopap2.0.co2 · Cited by 667
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Greco, F., & Vicent, M. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.006 · Cited by 652
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633
Greten, F. R., Arkan, M. C., Bollrath, J., Hsu, L.-C., Goode, J., Miething, C., Göktuna, S. I., Neuenhahn, M., Fierer, J., Paxian, S., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.009 · Cited by 616
Greish, K. (2007) · Journal of Drug Targeting · doi:10.1080/10611860701539584 · Cited by 600
Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity
Marusyk, A., Tabassum, D. P., Altrock, P. M., Almendro, V., Michor, F., & Polyak, K. (2014) · Nature · doi:10.1038/nature13556 · Cited by 597
You, J., Zhang, G., & Li, C. (2010) · ACS Nano · doi:10.1021/nn901181c · Cited by 597
The rationale for targeting the LOX family in cancer
Barker, H. E., Cox, T. R., & Erler, J. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3319 · Cited by 590
Meng, H., Mai, W. X., Zhang, H., Xue, M., Xia, T., Lin, S., Wang, X., Zhao, Y., Ji, Z., Zink, J. I., et al. (2013) · ACS Nano · doi:10.1021/nn3044066 · Cited by 575
Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu456 · Cited by 574
Scanlan, M. J., Raj, B. K., Calvo, B., Garin-Chesa, P., Sanz-Moncasi, M. P., Healey, J. H., Old, L. J., & Rettig, W. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5657 · Cited by 574
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555
Hauschild, A., Agarwala, S. S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., Eggermont, A., Grabbe, S., Gonzalez, R., Gille, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7636 · Cited by 548
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G., Aktan, G., Ellis, C., Florance, A., Vukelja, S., Bischoff, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6725 · Cited by 547
Supramolecular Stacking of Doxorubicin on Carbon Nanotubes for In Vivo Cancer Therapy
Liu, Z., Fan, A. C., Rakhra, K., Sherlock, S., Goodwin, A., Chen, X., Yang, Q., Felsher, D. W., & Dai, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200902612 · Cited by 534
Liu, H., Chen, D., Li, L., Liu, T., Tan, L., Wu, X., & Tang, F. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201002820 · Cited by 530
DNA Origami Delivery System for Cancer Therapy with Tunable Release Properties
Zhao, Y.-X., Shaw, A., Zeng, X., Benson, E., Nyström, A. M., & Högberg, B. (2012) · ACS Nano · doi:10.1021/nn3022662 · Cited by 519
Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.240 · Cited by 510
Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal
Tsuruo, T., Naito, M., Tomida, A., Fujita, N., Mashima, T., Sakamoto, H., & Haga, N. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01345.x · Cited by 502
Cancer Theranostics with Near-Infrared Light-Activatable Multimodal Nanoparticles
Melancon, M. P., Zhou, M., & Li, C. (2011) · Accounts of Chemical Research · doi:10.1021/ar200022e · Cited by 499
Cellular Heterogeneity and Molecular Evolution in Cancer
Almendro, V., Marusyk, A., & Polyak, K. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163923 · Cited by 498
Hybrid Nanoparticles for Detection and Treatment of Cancer
Sailor, M. J., & Park, J. (2012) · Advanced Materials · doi:10.1002/adma.201200653 · Cited by 487
Multiple Drug Resistance Mechanisms in Cancer
Baguley, B. C. (2010) · Molecular Biotechnology · doi:10.1007/s12033-010-9321-2 · Cited by 478
Genetic heterogeneity and cancer drug resistance
Turner, N. C., & Reis-Filho, J. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70335-7 · Cited by 454
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438
Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431
Functionalized gold nanoparticles: Synthesis, structure and colloid stability
Zhou, J., Ralston, J., Sedev, R., & Beattie, D. A. (2009) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2008.12.002 · Cited by 417
Nanoparticle-mediated Hyperthermia in Cancer Therapy
Chatterjee, D. K., Diagaradjane, P., & Krishnan, S. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.72 · Cited by 417
Herbst, R. S., Sun, Y., Eberhardt, W. E., Germonpré, P., Saijo, N., Zhou, C., Wang, J., Li, L., Kabbinavar, F., Ichinose, Y., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70132-7 · Cited by 415
Dieci, M. V., Arnedos, M., Andre, F., & Soria, J. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0362 · Cited by 406
Zhang, Q., Re Ko, N., & Kwon Oh, J. (2012) · Chemical Communications · doi:10.1039/c2cc32408c · Cited by 395
Enhancing the Toxicity of Cancer Chemotherapeutics with Gold Nanorod Hyperthermia
Hauck, T. S., Jennings, T. L., Yatsenko, T., Kumaradas, J. C., & Chan, W. C. W. (2008) · Advanced Materials · doi:10.1002/adma.200800921 · Cited by 395
Carbon nanotubes for biomedical imaging: The recent advances
Gong, H., Peng, R., & Liu, Z. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.10.002 · Cited by 389
Evaluation of Combination Chemotherapy
Zhao, L., Wientjes, M. G., & Au, J. L.-S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1087 · Cited by 379
Targeting multiple signal transduction pathways through inhibition of Hsp90
Zhang, H., & Burrows, F. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0549-9 · Cited by 377
Mathews Griner, L. A., Guha, R., Shinn, P., Young, R. M., Keller, J. M., Liu, D., Goldlust, I. S., Yasgar, A., McKnight, C., Boxer, M. B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311846111 · Cited by 377
An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition
Seguin, L., Kato, S., Franovic, A., Camargo, M. F., Lesperance, J., Elliott, K. C., Yebra, M., Mielgo, A., Lowy, A. M., Husain, H., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2953 · Cited by 374
Friday, B. B., & Adjei, A. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4790 · Cited by 374
Pharmaceutical nanotechnology for oral delivery of anticancer drugs
Mei, L., Zhang, Z., Zhao, L., Huang, L., Yang, X.-L., Tang, J., & Feng, S.-S. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.11.005 · Cited by 373
Greger, J. G., Eastman, S. D., Zhang, V., Bleam, M. R., Hughes, A. M., Smitheman, K. N., Dickerson, S. H., Laquerre, S. G., Liu, L., & Gilmer, T. M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0989 · Cited by 363
Liao, L., Liu, J., Dreaden, E. C., Morton, S. W., Shopsowitz, K. E., Hammond, P. T., & Johnson, J. A. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502011g · Cited by 362
DNA Nanoparticles and Development of DNA Delivery Vehicles for Gene Therapy
Vijayanathan, V., Thomas, T., & Thomas, T. J. (2002) · Biochemistry · doi:10.1021/bi0203987 · Cited by 360
Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands
Chou, T.-C. (1976) · Journal of Theoretical Biology · doi:10.1016/0022-5193(76)90169-7 · Cited by 349
Targeting the Tumor Microenvironment for Cancer Therapy
Sounni, N. E., & Noel, A. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.185363 · Cited by 344
Di Corato, R., Béalle, G., Kolosnjaj-Tabi, J., Espinosa, A., Clément, O., Silva, A. K. A., Ménager, C., & Wilhelm, C. (2015) · ACS Nano · doi:10.1021/nn506949t · Cited by 339
Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance
Creixell, M., & Peppas, N. A. (2012) · Nano Today · doi:10.1016/j.nantod.2012.06.013 · Cited by 331
Mayer, L. D., Harasym, T. O., Tardi, P. G., Harasym, N. L., Shew, C. R., Johnstone, S. A., Ramsay, E. C., Bally, M. B., & Janoff, A. S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0118 · Cited by 331
Circumventing Tumor Resistance to Chemotherapy by Nanotechnology
Liang, X.-J., Chen, C., Zhao, Y., & Wang, P. C. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_21 · Cited by 330
Cocoon-Like Self-Degradable DNA Nanoclew for Anticancer Drug Delivery
Sun, W., Jiang, T., Lu, Y., Reiff, M., Mo, R., & Gu, Z. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5088024 · Cited by 329
Yang, L., Moss, T., Mangala, L. S., Marini, J., Zhao, H., Wahlig, S., Armaiz‐Pena, G., Jiang, D., Achreja, A., Win, J., et al. (2014) · Molecular Systems Biology · doi:10.1002/msb.20134892 · Cited by 326
Park, S. Y., Gönen, M., Kim, H. J., Michor, F., & Polyak, K. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40724 · Cited by 324
Patil, Y. B., Swaminathan, S. K., Sadhukha, T., Ma, L., & Panyam, J. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.048 · Cited by 304
Nanotechnology applied to overcome tumor drug resistance
Gao, Z., Zhang, L., & Sun, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.051 · Cited by 303
Patel, N. M., Nozaki, S., Shortle, N. H., Bhat-Nakshatri, P., Newton, T. R., Rice, S., Gelfanov, V., Boswell, S. H., Goulet, R. J., Sledge, G. W., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203768 · Cited by 294
Nanoscale double emulsions stabilized by single-component block copolypeptides
Hanson, J. A., Chang, C. B., Graves, S. M., Li, Z., Mason, T. G., & Deming, T. J. (2008) · Nature · doi:10.1038/nature07197 · Cited by 290
Wu, H., Hait, W. N., & Yang, J. (2003) · PubMed · Cited by 289
He, C., Liu, D., & Lin, W. (2015) · ACS Nano · doi:10.1021/nn506963h · Cited by 274
Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis
Larsen, A. K., Ouaret, D., El Ouadrani, K., & Petitprez, A. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.012 · Cited by 267
The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer
Hilger, R. A., Scheulen, M. E., & Strumberg, D. (2002) · Oncology Research and Treatment · doi:10.1159/000068621 · Cited by 265
New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors
FAIVRE, S., DJELLOUL, S., & RAYMOND, E. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.005 · Cited by 264
Time-programmed dual release formulation by multilayered drug-loaded nanofiber meshes
Okuda, T., Tominaga, K., & Kidoaki, S. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.12.029 · Cited by 263
Song, X., Liang, C., Gong, H., Chen, Q., Wang, C., & Liu, Z. (2015) · Small · doi:10.1002/smll.201500550 · Cited by 262
Electronic Structure and Optical Properties of Gold Nanoshells
Prodan, E., Nordlander, P., & Halas, N. J. (2003) · Nano Letters · doi:10.1021/nl034594q · Cited by 257
Targeting cancer stem cells to suppress acquired chemotherapy resistance
Vidal, S. J., Rodriguez-Bravo, V, Galsky, M., Cordon-Cardo, C., & Domingo-Domenech, J. (2014) · Oncogene · doi:10.1038/onc.2013.411 · Cited by 242
Small RNA combination therapy for lung cancer
Xue, W., Dahlman, J. E., Tammela, T., Khan, O. F., Sood, S., Dave, A., Cai, W., Chirino, L. M., Yang, G. R., Bronson, R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412686111 · Cited by 242
Shvedova, A. A., Kagan, V. E., & Fadeel, B. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105819 · Cited by 242
Applications of Functionalized Fullerenes in Tumor Theranostics
Chen, Z., Ma, L., Liu, Y., & Chen, C. (2012) · Theranostics · doi:10.7150/thno.3509 · Cited by 237
Folic acid-conjugated graphene oxide for cancer targeted chemo-photothermal therapy
Qin, X. C., Guo, Z. Y., Liu, Z. M., Zhang, W., Wan, M. M., & Yang, B. W. (2013) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2012.12.005 · Cited by 236
Yi, X., Yang, K., Liang, C., Zhong, X., Ning, P., Song, G., Wang, D., Ge, C., Chen, C., Chai, Z., et al. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201502003 · Cited by 234
Dynamic Magnetic Fields Remote-Control Apoptosis via Nanoparticle Rotation
Zhang, E., Kircher, M. F., Koch, M., Eliasson, L., Goldberg, S. N., & Renström, E. (2014) · ACS Nano · doi:10.1021/nn406302j · Cited by 232
Hyperthermia-induced drug targeting
May, J. P., & Li, S.-D. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.758631 · Cited by 228
Chloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer
Cook, K. L., Wärri, A., Soto-Pantoja, D. R., Clarke, P. A., Cruz, M. I., Zwart, A., & Clarke, R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3227 · Cited by 226
You, J., Zhang, R., Zhang, G., Zhong, M., Liu, Y., Van Pelt, C. S., Liang, D., Wei, W., Sood, A. K., & Li, C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.028 · Cited by 211
The Origins and Implications of Intratumor Heterogeneity
Michor, F., & Polyak, K. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0234 · Cited by 209
Zheng, C., Zheng, M., Gong, P., Deng, J., Yi, H., Zhang, P., Zhang, Y., Liu, P., Ma, Y., & Cai, L. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.053 · Cited by 200
Zonder, J. A., Crowley, J., Hussein, M. A., Bolejack, V., Moore, D. F., Whittenberger, B. F., Abidi, M. H., Durie, B. G. M., & Barlogie, B. (2010) · Blood · doi:10.1182/blood-2010-08-303487 · Cited by 194
Enhanced Anticancer Efficacy by ATP‐Mediated Liposomal Drug Delivery
Mo, R., Jiang, T., & Gu, Z. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201400268 · Cited by 194
Combination Drug Delivery Approaches in Metastatic Breast Cancer
Lee, J. H., & Nan, A. (2012) · Journal of Drug Delivery · doi:10.1155/2012/915375 · Cited by 192
Morton, S. W., Lee, M. J., Deng, Z. J., Dreaden, E. C., Siouve, E., Shopsowitz, K. E., Shah, N. J., Yaffe, M. B., & Hammond, P. T. (2014) · Science Signaling · doi:10.1126/scisignal.2005261 · Cited by 190
van Rijt, S. H., Bölükbas, D. A., Argyo, C., Datz, S., Lindner, M., Eickelberg, O., Königshoff, M., Bein, T., & Meiners, S. (2015) · ACS Nano · doi:10.1021/nn5070343 · Cited by 188
Lee, S., Park, H., & Yoo, K. (2010) · Advanced Materials · doi:10.1002/adma.201001040 · Cited by 177
Peiris, P. M., Bauer, L., Toy, R., Tran, E., Pansky, J., Doolittle, E., Schmidt, E., Hayden, E., Mayer, A., Keri, R. A., et al. (2012) · ACS Nano · doi:10.1021/nn300652p · Cited by 177
Drug Targeting Strategies in Cancer Treatment: An Overview
L. Arias, J. (2011) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955711793564024 · Cited by 176
p53 and NF-κB Coregulate Proinflammatory Gene Responses in Human Macrophages
Lowe, J. M., Menendez, D., Bushel, P. R., Shatz, M., Kirk, E. L., Troester, M. A., Garantziotis, S., Fessler, M. B., & Resnick, M. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1070 · Cited by 171
You, J., Shao, R., Wei, X., Gupta, S., & Li, C. (2010) · Small · doi:10.1002/smll.201000028 · Cited by 170
Stimulated Release of Size‐Selected Cargos in Succession from Mesoporous Silica Nanoparticles
Wang, C., Li, Z., Cao, D., Zhao, Y., Gaines, J. W., Bozdemir, O. A., Ambrogio, M. W., Frasconi, M., Botros, Y. Y., Zink, J. I., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201107960 · Cited by 169
Pan, H., Liu, L., & Cai, L. (2022) · Biomaterial Engineering · doi:10.1007/978-981-16-5419-0_18 · Cited by 165
Finn, R. S., Press, M. F., Dering, J., Arbushites, M., Koehler, M., Oliva, C., Williams, L. S., & Di Leo, A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1925 · Cited by 164
Ashwell, S., & Zabludoff, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5138 · Cited by 163
Susa, M., Iyer, A. K., Ryu, K., Choy, E., Hornicek, F. J., Mankin, H. J., Milane, L. S., Amiji, M. M., & Duan, Z. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010764 · Cited by 162
Pistollato, F., Giampieri, F., & Battino, M. A. (2014) · Food and Chemical Toxicology · doi:10.1016/j.fct.2014.11.004 · Cited by 161
Peng, C.-L., Shieh, M.-J., Tsai, M.-H., Chang, C.-C., & Lai, P.-S. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.05.018 · Cited by 160
Hu, S.-H., Chen, S.-Y., & Gao, X. (2012) · ACS Nano · doi:10.1021/nn205023w · Cited by 158
Lança, T., & Silva‐Santos, B. (2012) · OncoImmunology · doi:10.4161/onci.20068 · Cited by 156
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis
Gouill, S. L., Podar, K., Amiot, M., Hideshima, T., Chauhan, D., Ishitsuka, K., Kumar, S. K., Raje, N. S., Richardson, P. G. G., Harousseau, J., et al. (2004) · Blood · doi:10.1182/blood-2004-05-1760 · Cited by 155
Peng, C., Lai, P., Lin, F., Wu, S. Y.-H., & Shieh, M. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.03.048 · Cited by 150
Programmable nanomedicine: synergistic and sequential drug delivery systems
Pacardo, D. B., Ligler, F. S., & Gu, Z. (2015) · Nanoscale · doi:10.1039/c4nr07677j · Cited by 144
Tao, Y., Ju, E., Liu, Z., Dong, K., Ren, J., & Qu, X. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.04.073 · Cited by 143
Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen
Shoman, N. M., Klassen, S., McFadden, A., Bickis, M., Torlakovic, E., & Chibbar, R. (2004) · Modern Pathology · doi:10.1038/modpathol.3800296 · Cited by 142
Multi-Drug Resistance in Cancer
(2009) · Methods in molecular biology · doi:10.1007/978-1-60761-416-6 · Cited by 139
Stark, D., Nankivell, M. G., Pujade-Lauraine, É., Kristensen, G. B., Elit, L., Stockler, M. R., Hilpert, F., Cervantes, A. M. R., Brown, J. M., Lanceley, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70567-3 · Cited by 137
Poon, C. J., He, C., Liu, D., Lu, K., & Lin, W. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.026 · Cited by 136
Shi, J., Liu, Y., Wang, L., Gao, J., Zhang, J., Yu, X., Ma, R., Liu, R., & Zhang, Z. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.10.037 · Cited by 131
Cisplatin-tethered gold nanospheres for multimodal chemo-radiotherapy of glioblastoma
Setua, S., Ouberai, M. M., Piccirillo, S. G. M., Watts, C., & Welland, M. E. (2014) · Nanoscale · doi:10.1039/c4nr03693j · Cited by 130
Cytokines, NF-κB, Microenvironment, Intestinal Inflammation and Cancer
Schottelius, A. J. G., & Dinter, H. (2006) · Cancer treatment and research · doi:10.1007/0-387-26283-0_3 · Cited by 129
Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy
Chu, K. S., Schorzman, A. N., Finniss, M. C., Bowerman, C. J., Peng, L., Luft, J. C., Madden, A. J., Wang, A. Z., Zamboni, W. C., & DeSimone, J. M. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.038 · Cited by 129
Li, S.-Y., Sun, R., Wang, H., Shen, S., Liu, Y., Du, X., Zhu, Y., & Jun, W. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.011 · Cited by 128
Uzgare, A. R., Kaplan, P. J., & Greenberg, N. M. (2003) · The Prostate · doi:10.1002/pros.10212 · Cited by 128
Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy
Xu, L., Pirollo, K. F., & Chang, E. H. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00324-8 · Cited by 128
Zalba, S., Contreras-Sandoval, A. M., Haeri, A., ten Hagen, T. L. M., Navarro-Blasco, Í., Koning, G. A., & Garrido, M. J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.271 · Cited by 127
Kim, Y., Na, H., Kim, S., Jang, H., Chang, S., & Min, D. (2015) · Small · doi:10.1002/smll.201402269 · Cited by 126
Synthetic Aptamer-Polymer Hybrid Constructs for Programmed Drug Delivery into Specific Target Cells
Oh, S. S., Lee, B. F., Leibfarth, F. A., Eisenstein, M. S., Robb, M. J., Lynd, N. A., Hawker, C. J., & Soh, H. T. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5079464 · Cited by 116
Tumor Heterogeneity Confounds and Illuminates: Assessing the implications
Kleppe, M., & Levine, R. L. (2014) · Nature Medicine · doi:10.1038/nm.3522 · Cited by 114
Duong, H. T. T., Marquis, C. P., Whittaker, M. R., Davis, T. P., & Boyer, C. A. (2011) · Macromolecules · doi:10.1021/ma201085z · Cited by 113
Narayanan, S., Mony, U., Vijaykumar, D. K., Koyakutty, M., Paul‐Prasanth, B., & Menon, D. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.03.015 · Cited by 112
Liu, H., Chen, D., Li, L., Liu, T., Tan, L., Wu, X., & Tang, F. (2010) · Angewandte Chemie · doi:10.1002/ange.201002820 · Cited by 109
Multifunctional hollow gold nanoparticles designed for triple combination therapy and CT imaging
Park, J., Park, J. H., Ju, E. J., Park, S. S., Choi, J., Lee, J. H., Lee, K. J., Shin, S. H., Ko, E. J., Park, I., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.007 · Cited by 107
Choi, S., Henderson, M. J., Kwan, E., Beesley, A. H., Sutton, R., Bahar, A. Y., Giles, J. E., Venn, N. C., Pozza, L. D., Baker, D. L., et al. (2007) · Blood · doi:10.1182/blood-2007-01-067785 · Cited by 106
Conte, C., Ungaro, F., Maglio, G., Tirino, P., Siracusano, G., Sciortino, M. T., Leone, N., Palma, G., Barbieri, A., Arra, C., et al. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.12.026 · Cited by 106
Baronzio, G., Parmar, G., & Baronzio, M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00165 · Cited by 105
Restoration of p53 to limit tumor growth
Wang, W., & El‐Deiry, W. S. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f31d6f · Cited by 105
Drug delivery systems for differential release in combination therapy
Zhang, H., Wang, G., & Yang, H. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.547470 · Cited by 105
Cited by
Recent progress in drug delivery
Li, C., Wang, J., Wang, Y., Gao, H., Wei, G., Huang, Y., Yu, H., Gan, Y., Wang, Y., Mei, L., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.003 · Cited by 818
Recent Advances in Cell Membrane–Camouflaged Nanoparticles for Cancer Phototherapy
Zhen, X., Cheng, P., & Pu, K. (2019) · Small · doi:10.1002/smll.201804105 · Cited by 483
Recent progress in nanomedicine for enhanced cancer chemotherapy
Wei, G., Wang, Y., Yang, G., Wang, Y., & Ju, R. (2021) · Theranostics · doi:10.7150/thno.57828 · Cited by 463
Recent Advances in Subcellular Targeted Cancer Therapy Based on Functional Materials
Chen, W., Luo, G., & Zhang, X. (2019) · Advanced Materials · doi:10.1002/adma.201802725 · Cited by 373
Kwon, S., Ko, H., You, D. G., Kataoka, K., & Park, J. H. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00136 · Cited by 370
Metadata
- Authors
- Kemp, J. A., Shim, M. S., Heo, C. Y., & Kwon, Y. J.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 98
- Pages
- 3-18
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2151467658
- Cited by
- 506
- References
- 241
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.